UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________

FORM 8-K

___________________________

Current Report

Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~September~~October 1030, 2025

___________________________

TRAVERE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

___________________________

Delaware

001-36257

27-4842691

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

3611 Valley Centre Drive, Suite 300

San Diego, CA 92130

(Address of Principal Executive Offices, including Zip Code)

(888) 969-7879

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

TVTX

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 82.0102 ~~Other~~Results ~~Events~~of Operations and Financial Condition.

On ~~September 10~~October 30, 2025, Travere Therapeutics, Inc. (the “Company”) ~~announced~~issued ~~that~~a ~~the~~press ~~U.S.~~release ~~Food~~announcing, ~~and~~among ~~Drug~~other ~~Administration~~things, ~~(“FDA”)~~its ~~has~~financial ~~informed~~results ~~the~~for ~~Company that following further review of~~ the ~~supplemental~~quarter ~~New~~ended ~~Drug Application (“sNDA”) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (“FSGS”)~~September 30, ~~an advisory committee is no longer needed~~2025. ~~The~~A ~~sNDA~~copy ~~remains~~of ~~under review by~~ the ~~FDA~~press ~~with~~release aand ~~Prescription~~accompanying ~~Drug~~information ~~User~~is ~~Fee~~attached ~~Act~~as ~~(“PDUFA”)~~Exhibit ~~target~~99.1 ~~action~~to ~~date~~this ofcurrent ~~January 13, 2026~~report.

IfThe ~~approved~~information in this Item 2.02, ~~FILSPARI~~and ~~would~~Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the ~~first~~purposes ~~medication~~of ~~indicated~~Section ~~for~~18 ~~FSGS~~of the Securities Exchange Act of 1934, aas ~~rare~~amended, ~~and~~or ~~serious~~otherwise ~~kidney~~subject ~~disorder~~to ~~driven~~the byliabilities ~~proteinuria~~of that ~~leads~~Section. toThe ~~progressive~~information ~~kidney~~in ~~function~~this ~~loss~~Item 2.02, and ~~kidney~~Exhibit ~~failure~~99.1 ~~FILSPARI~~attached ishereto, anshall ~~oral,~~not ~~non-immunosuppressive~~be ~~potential~~incorporated ~~therapy~~by ~~that~~reference ~~targets~~into ~~podocyte~~any ~~injury~~registration statement or other document filed with the Securities and Exchange Commission, awhether ~~key~~filed ~~driver~~before or after the date hereof regardless of ~~FSGS~~any ~~progression~~general incorporation language in any such filing, unless the registrant expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.

~~The~~Item ~~sNDA is supported by two of the largest and most rigorous head-to-head interventional studies conducted to date in FSGS, the Phase 3 DUPLEX Study and the Phase 2 DUET Study~~9.01 Financial InStatements ~~these studies, FILSPARI demonstrated rapid, superior~~ and ~~sustained reductions in proteinuria when compared with maximum labeled dose irbesartan across adult and pediatric patients~~Exhibits. As published in the New England Journal of Medicine, DUPLEX showed statistically significant and clinically meaningful proteinuria remission at 36 weeks that was durable through 2 years. Patients who achieved partial or complete proteinuria remission in the DUPLEX Study, irrespective of the treatment arm, had a 67% to 77% lower risk of kidney failure, respectively, with the treatment effect of FILSPARI strengthened at more stringent thresholds down to complete remission. The results from these studies are in alignment with the findings of the independent PARASOL workgroup that support the importance of proteinuria in FSGS.

~~FILSPARI~~(d) Exhibits was well-tolerated in the studies with a safety profile consistent across trials and comparable to irbesartan. FILSPARI is fully approved by the FDA and EMA to slow kidney function decline in adults with IgA nephropathy.

About the DUPLEX and DUET Studies


Exhibit No.						Description
99.1						Press release of Travere Therapeutics, Inc. dated October 30 , 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

The Phase 3 DUPLEX Study is the largest interventional study to date in FSGS, and the only study in FSGS against a maximally dosed active comparator. While DUPLEX achieved its pre-specified interim FSGS partial remission of proteinuria (“FPRE”) endpoint with statistical significance at 36 weeks, it did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment. The two-year results from the study were published in the New England Journal of Medicine and showed that FILSPARI delivered clinically meaningful benefit at 108 weeks with significant proteinuria reduction, higher rates of partial and complete remission, and a lower rate of end-stage kidney disease compared to active control. The Phase 2 DUET Study of FILSPARI in FSGS met the primary efficacy endpoint for the combined treatment group, demonstrating a greater than two-fold reduction in proteinuria compared to irbesartan. FILSPARI was well-tolerated with a safety profile that was consistent across all clinical trials conducted to date and comparable to the maximally dosed active control, irbesartan, including no drug-induced liver injury and no fluid overload. Patients who completed the DUPLEX and DUET double-blind portions of the studies on treatment were eligible to participate in the open-label extension of the trials.

Forward-Looking Statements

This report contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words “on-track,” “positioned,” “look forward to,” “will,” “would,” “may,” “might,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” or similar expressions. In addition, expressions of strategies, intentions or plans are also forward-looking statements. Such forward-looking statements include, but are not limited to, references to: statements relating to the clinical studies and data described herein; statements and expectations regarding the FDA’s ongoing review of the sNDA for FILSPARI in FSGS, and the timing and outcome thereof; statements regarding the potential for FILSPARI to be the first medication indicated for FSGS; and statements related to the estimated sizes of patient populations. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties related to the Company’s sNDA for FILSPARI in FSGS, including the timing and outcome thereof. There is no guarantee that the FDA will grant approval of FILSPARI for FSGS on the anticipated timeline, or at all. The Company also faces risks and uncertainties related to its business and finances in general, the success of its commercial products, risks and uncertainties associated with its preclinical and clinical stage pipeline, risks and uncertainties associated with the regulatory review and approval process, risks and uncertainties associated with enrollment of clinical trials for rare diseases, and risks that ongoing or planned clinical trials may not succeed or may be delayed for safety, regulatory or other reasons. Specifically, the Company faces risks associated with the ongoing commercial launch of FILSPARI in IgAN, the timing and potential outcome of its and its partners’ clinical studies, market acceptance of its commercial products including efficacy, safety, price, reimbursement, and benefit over competing therapies, risks related to the challenges of manufacturing scale-up, risks associated with the successful development and execution of commercial strategies for such products, including FILSPARI, and risks and uncertainties related to the new administration, including but not limited to risks and uncertainties related to tariffs and the funding, staffing and prioritization of resources at government agencies including the FDA. The Company also faces the risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates, including as a result of macroeconomic conditions; risks relating to the Company’s dependence on contractors for clinical drug supply and commercial manufacturing; uncertainties relating to patent protection and exclusivity periods and intellectual property rights of third parties; risks associated with regulatory interactions; and risks and uncertainties relating to competitive products, including current and potential future generic competition with certain of the Company’s products, and technological changes that may limit demand for the Company’s products. The Company also faces additional risks associated with global and macroeconomic conditions, including health epidemics and pandemics, including risks related to potential disruptions to clinical trials, commercialization activity, supply chain, and manufacturing operations. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond the Company’s control. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of

new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties, including under the heading “Risk Factors”, as included in the Company’s most recent Form 10-K, Form 10-Q and other filings with the Securities and Exchange Commission.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRAVERE THERAPEUTICS, INC.

Dated: September 10, 2025

By:

/s/ Eric Dube

Dated: October 30, 2025

By:

/s/ Eric Dube

Name:

Eric Dube

Title:

Chief Executive Officer

Filing Compare · Travere Therapeutics, Inc.